BBC vs. VRAI
BBC (Virtus LifeSci Biotech Clinical Trials ETF) and VRAI (Virtus Real Asset Income ETF) are both exchange-traded funds - BBC is a Health & Biotech Equities fund tracking the LifeSci Biotechnology Clinical Trials Index, while VRAI is a REIT fund tracking the Indxx Real Asset Income Index. Both are passively managed. Over the past 5 years, BBC returned -0.26%/yr vs 5.71%/yr for VRAI. At a 0.38 correlation, their price movements are largely independent. BBC charges 0.79%/yr vs 0.55%/yr for VRAI.
Performance
BBC vs. VRAI - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, BBC achieves a 25.75% return, which is significantly higher than VRAI's 20.17% return.
BBC
- 1D
- 1.59%
- 1M
- 13.54%
- YTD
- 25.75%
- 6M
- 22.73%
- 1Y
- 156.95%
- 3Y*
- 27.00%
- 5Y*
- -0.26%
- 10Y*
- 11.15%
VRAI
- 1D
- 0.52%
- 1M
- -1.36%
- YTD
- 20.17%
- 6M
- 20.99%
- 1Y
- 22.60%
- 3Y*
- 12.35%
- 5Y*
- 5.71%
- 10Y*
- —
BBC vs. VRAI - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|
BBC Virtus LifeSci Biotech Clinical Trials ETF | 25.75% | 63.77% | -1.11% | -1.80% | -35.13% | -22.31% | 30.32% | 51.68% |
VRAI Virtus Real Asset Income ETF | 20.17% | 6.67% | 2.66% | 6.12% | -9.96% | 24.35% | -5.94% | 6.05% |
Correlation
The correlation between BBC and VRAI is 0.08, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.08 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.30 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.35 |
Correlation (All Time) Calculated using the full available price history since Feb 8, 2019 | 0.38 |
Over the past year, the correlation between BBC and VRAI has dropped to 0.08 - well below their long-term average of 0.38, suggesting their price drivers have been diverging.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
BBC vs. VRAI — Risk / Return Rank
BBC
VRAI
BBC vs. VRAI - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Virtus LifeSci Biotech Clinical Trials ETF (BBC) and Virtus Real Asset Income ETF (VRAI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| BBC | VRAI | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +2.46 | ||
| Sortino ratioReturn per unit of downside risk | +1.99 | ||
| Omega ratioGain probability vs. loss probability | 1.56 | 1.33 | +0.23 |
| Calmar ratioReturn relative to maximum drawdown | 10.46 | 4.71 | +5.75 |
| Martin ratioReturn relative to average drawdown | 30.65 | 14.54 | +16.11 |
Loading charts...
Drawdowns
BBC vs. VRAI - Drawdown Comparison
The maximum BBC drawdown since its inception was -76.85%, which is greater than VRAI's maximum drawdown of -47.51%. Use the drawdown chart below to compare losses from any high point for BBC and VRAI.
Loading charts...
Drawdown Indicators
| BBC | VRAI | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -76.85% | -47.51% | -29.34% |
Max Drawdown (1Y)Largest decline over 1 year | -15.10% | -4.82% | -10.28% |
Max Drawdown (3Y)Largest decline over 3 years | -54.45% | -16.89% | -37.56% |
Max Drawdown (5Y)Largest decline over 5 years | -71.97% | -26.71% | -45.26% |
Max Drawdown (10Y)Largest decline over 10 years | -76.85% | — | — |
Current DrawdownCurrent decline from peak | -19.28% | -2.34% | -16.94% |
Average DrawdownAverage peak-to-trough decline | -37.08% | -10.03% | -27.05% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 5.14% | 1.56% | +3.58% |
Volatility
BBC vs. VRAI - Volatility Comparison
Virtus LifeSci Biotech Clinical Trials ETF (BBC) has a higher volatility of 12.08% compared to Virtus Real Asset Income ETF (VRAI) at 3.28%. This indicates that BBC's price experiences larger fluctuations and is considered to be riskier than VRAI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| BBC | VRAI | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 12.08% | 3.28% | +8.80% |
Volatility (6M)Calculated over the trailing 6-month period | 26.79% | 8.29% | +18.50% |
Volatility (1Y)Calculated over the trailing 1-year period | 36.27% | 11.99% | +24.28% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 39.52% | 16.61% | +22.91% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 37.75% | 22.07% | +15.68% |
BBC vs. VRAI - Expense Ratio Comparison
BBC has a 0.79% expense ratio, which is higher than VRAI's 0.55% expense ratio.
Dividends
BBC vs. VRAI - Dividend Comparison
BBC's dividend yield for the trailing twelve months is around 1.35%, less than VRAI's 2.92% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
BBC Virtus LifeSci Biotech Clinical Trials ETF | 1.35% | 1.70% | 1.00% | 0.34% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 2.09% | 0.00% | 0.51% |
VRAI Virtus Real Asset Income ETF | 2.92% | 4.68% | 7.13% | 5.02% | 4.48% | 3.34% | 3.91% | 2.80% | 0.00% | 0.00% | 0.00% | 0.00% |
Frequently Asked Questions
BBC and VRAI have a correlation of 0.08, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
BBC has higher volatility (12.08%) compared to VRAI (3.28%). In terms of maximum drawdown, BBC dropped -76.85% vs VRAI's -47.51%.
On 5-year performance, VRAI leads with 5.71% vs -0.26% for BBC. On fees, VRAI is cheaper at 0.55% per year. On volatility, VRAI has been the lower-risk option at 3.28%. The better choice depends on whether you care most about return, fees, risk, or income.
Over the 5-year period, VRAI has performed better with a 5.71% return vs -0.26%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.
VRAI is cheaper with a 0.55% expense ratio, compared with 0.79% for BBC.
VRAI has the higher dividend yield at 2.92%, compared with 1.35% for BBC.
BBC is categorized as Health & Biotech Equities, while VRAI is REIT. BBC tracks LifeSci Biotechnology Clinical Trials Index, while VRAI tracks Indxx Real Asset Income Index. Their fees differ too: 0.79% for BBC and 0.55% for VRAI.
BBC currently has the higher Sharpe Ratio (4.36 vs 1.90), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for BBC and VRAI
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer